Promising future for Cubist's Sivextro in anti-MRSA sector

4 April 2014

Following its launch, Cubist Pharmaceutical’s (Nasdaq: CBST) second generation oxazolidinone Sivextro Sivextro will be highly differentiated from other anti-MRSA (methicillin-resistant Staphylococcus aureus) agents for the treatment of complicated skin and skin structure infections (cSSSIs) due to MRSA, according to a new report from Decision Resources.

In particular, Sivextro's once-daily dosing, shorter course of therapy, and its potential for lower treatment-related adverse events are notable improvements over Pfizer's (NYSE: PFE) Zyvox/Zyvoxid (linezolid), the current market share leader for MRSA cSSSIs. Accordingly, the Food and Drug Administration's Anti-Infective Drugs Advisory Committee unanimously recently recommended Sivextro's approval for the treatment of cSSSIs (The Pharma Letter April 2).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >